Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

dentsply sirona inc. - XRAY

XRAY

Close Chg Chg %
11.68 -0.02 -0.13%

Closed Market

11.67

-0.02 (0.13%)

Volume: 3.10M

Last Updated:

Mar 26, 2026, 4:00 PM EDT

Trade Now

Company Overview: dentsply sirona inc. - XRAY

XRAY Key Data

Open

$11.49

 Day Range

11.49 - 12.16

52 Week Range

9.85 - 17.18

 Market Cap

$2.33B

Shares Outstanding

199.75M

 Public Float

198.44M

Beta

0.98

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$3.00

Yield

547.95%

 Dividend

$0.16

EX-DIVIDEND DATE

Dec 26, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

5.34M

  

XRAY Performance

1 Week
 
 6.67%
 
1 Month
 
 -20.44%
 
3 Months
 
 1.39%
 
1 Year
 
 -21.77%
 
5 Years
 
 -80.94%
 

XRAY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 16
Full Ratings ➔

About dentsply sirona inc. - XRAY

Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment is engaged in designing, manufacturing, and selling dental technology and equipment products. The Essential Dental Solutions segment designs, manufactures, and sells value-added endodontic, restorative, and preventive consumable products. The Orthodontic and Implant Solutions segment designs, manufactures, and sells various digital implant systems and dental implant products. The Wellspect Healthcare segment designs, manufactures, and sells continence care solutions for management of both urinary and bowel dysfunction dental products. The company was founded in 1899 and is headquartered in Charlotte, NC.

XRAY At a Glance

Dentsply Sirona, Inc.
13320 Ballantyne Corporate Place
Charlotte, North Carolina 28277-3607
Phone 1-844-848-0137 Revenue 3.68B
Industry Medical Specialties Net Income -598,000,000.00
Sector Health Technology Employees 14,000
Fiscal Year-end 12 / 2026
View SEC Filings

XRAY Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.619
Price to Book Ratio 1.704
Price to Cash Flow Ratio 9.70
Enterprise Value to EBITDA 7.309
Enterprise Value to Sales 1.202
Total Debt to Enterprise Value 0.558

XRAY Efficiency

Revenue/Employee 262,857.143
Income Per Employee -42,714.286
Receivables Turnover 4.993
Total Asset Turnover 0.658

XRAY Liquidity

Current Ratio 1.506
Quick Ratio 1.028
Cash Ratio 0.243

XRAY Profitability

Gross Margin 50.00
Operating Margin 6.875
Pretax Margin -13.207
Net Margin -16.25
Return on Assets -10.696
Return on Equity -36.452
Return on Total Capital -15.708
Return on Invested Capital -16.926

XRAY Capital Structure

Total Debt to Total Equity 184.317
Total Debt to Total Capital 64.828
Total Debt to Total Assets 45.46
Long-Term Debt to Equity 157.431
Long-Term Debt to Total Capital 55.372
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Dentsply Sirona Inc. - XRAY

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
3.92B 3.96B 3.79B 3.68B
Sales Growth
-7.30% +1.10% -4.34% -2.98%
Cost of Goods Sold (COGS) incl D&A
1.79B 1.88B 1.82B 1.84B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
328.00M 343.00M 349.00M 352.00M
Depreciation
119.00M 132.00M 133.00M 141.00M
Amortization of Intangibles
209.00M 211.00M 216.00M 211.00M
COGS Growth
-5.29% +4.69% -2.72% +0.82%
Gross Income
2.13B 2.09B 1.97B 1.84B
Gross Income Growth
-8.94% -1.92% -5.79% -6.50%
Gross Profit Margin
+54.31% +52.69% +51.89% +50.00%
2022 2023 2024 2025 5-year trend
SG&A Expense
1.76B 1.79B 1.74B 1.59B
Research & Development
174.00M 184.00M 165.00M 150.00M
Other SG&A
1.59B 1.61B 1.57B 1.44B
SGA Growth
+3.22% +1.76% -3.12% -8.69%
Other Operating Expense
- - - -
-
Unusual Expense
1.27B 386.00M 1.09B 645.00M
EBIT after Unusual Expense
(904.00M) (91.00M) (859.00M) (392.00M)
Non Operating Income/Expense
(101.00M) (20.00M) (22.00M) (12.00M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
50.00M 64.00M 55.00M 82.00M
Interest Expense Growth
-24.24% +28.00% -14.06% +49.09%
Gross Interest Expense
50.00M 64.00M 55.00M 82.00M
Interest Capitalized
- - - -
-
Pretax Income
(1.05B) (175.00M) (936.00M) (486.00M)
Pretax Income Growth
-293.58% +83.41% -434.86% +48.08%
Pretax Margin
-26.90% -4.41% -24.68% -13.21%
Income Tax
(105.00M) (43.00M) (26.00M) 112.00M
Income Tax - Current - Domestic
5.00M 1.00M (5.00M) 1.00M
Income Tax - Current - Foreign
118.00M 86.00M 115.00M 81.00M
Income Tax - Deferred - Domestic
(162.00M) 1.00M (62.00M) 38.00M
Income Tax - Deferred - Foreign
(66.00M) (131.00M) (74.00M) (8.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(950.00M) (132.00M) (910.00M) (598.00M)
Minority Interest Expense
- - - -
-
Net Income
(950.00M) (132.00M) (910.00M) (598.00M)
Net Income Growth
-331.14% +86.11% -589.39% +34.29%
Net Margin Growth
-24.22% -3.33% -23.99% -16.25%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(950.00M) (132.00M) (910.00M) (598.00M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(950.00M) (132.00M) (910.00M) (598.00M)
EPS (Basic)
-4.4084 -0.6226 -4.4784 -2.999
EPS (Basic) Growth
-334.25% +85.88% -619.31% +33.03%
Basic Shares Outstanding
215.50M 212.00M 203.20M 199.40M
EPS (Diluted)
-4.4084 -0.6226 -4.4784 -2.999
EPS (Diluted) Growth
-336.19% +85.88% -619.31% +33.03%
Diluted Shares Outstanding
215.50M 212.00M 203.20M 199.40M
EBITDA
695.00M 638.00M 579.00M 605.00M
EBITDA Growth
-28.86% -8.20% -9.25% +4.49%
EBITDA Margin
+17.72% +16.09% +15.26% +16.44%

Snapshot

Average Recommendation HOLD Average Target Price 14.50
Number of Ratings 16 Current Quarters Estimate 0.306
FY Report Date 03 / 2026 Current Year's Estimate 1.432
Last Quarter’s Earnings 0.27 Median PE on CY Estimate N/A
Year Ago Earnings 1.60 Next Fiscal Year Estimate 1.558
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 14 14 14
Mean Estimate 0.31 0.39 1.43 1.56
High Estimates 0.40 0.48 1.46 1.66
Low Estimate 0.22 0.33 1.40 1.45
Coefficient of Variance 17.03 14.89 1.21 3.66

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 2
OVERWEIGHT 1 0 1
HOLD 12 13 14
UNDERWEIGHT 0 0 0
SELL 0 1 1
MEAN Hold Hold Hold

Insider Actions for Dentsply Sirona Inc. - XRAY

Date Name Shares Transaction Value
Jan 14, 2026 Kevin J. Czerney VP, Chief Accounting Officer 341 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Daniel T. Scavilla President, CEO & Member of BOD; Director 17,945 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Jonathan J. Mazelsky Director 14,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Jonathan J. Mazelsky Director 28,847 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Kevin J. Czerney VP, Chief Accounting Officer 3,493 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Michael J. Barber Director 17,945 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Brian T. Gladden Director 29,042 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Gregory T. Lucier Director 24,901 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Betsy DeHaas Holden Director 54,614 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Kevin J. Czerney VP, Chief Accounting Officer 28,041 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Andrea L. Frohning SVP, CHRO 1,759 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Andrea L. Frohning SVP, CHRO 34,002 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Janet S. Vergis Director 44,501 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Willie A. Deese Director 57,748 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Leslie F. Varon Director 57,541 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Clyde R. Hosein Director 41,253 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Robert A. Johnson SVP, Chief Supply Chain Office 3,113 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Robert A. Johnson SVP, Chief Supply Chain Office 116,313 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Gregory T. Lucier Director 82,301 Bona fide gift 0.00
Aug 13, 2025 Gregory T. Lucier Director 24,047 Bona fide gift 0.00

Dentsply Sirona Inc. in the News